Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
Conference call and webcast details:
Investors (domestic): | 877-407-0792 | |
Investors (international): | 201-689-8263 | |
Conference ID: | 13739908 | |
To access a live webcast of the update, please use this link.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate, OMBLASTYS® (omburtamab), which targets tumors that express B7-H3.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model, including the Company’s plans and strategies, development, commercialization and product distribution plans,; expectations with respect to our products and product candidates including the potential of DANYELZA and product candidates based on the SADA technology and the potential benefits thereof; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’, “guidance” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to risks associated with our financial condition and need for additional capital; the risks that actual results of our restructuring plan and revised business plan announced in
DANYELZA®, OMBLASTYS® and Y-mAbs® are registered trademarks of
Investor Contact:
VP, Head of Investor Relations
[email protected]
Source: Y-mAbs Therapeutics, Inc